Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
NIHR Bioresource Rare Diseases, |
RCV000852216 | SCV000899921 | likely pathogenic | Hermansky-Pudlak syndrome | 2019-02-01 | criteria provided, single submitter | research | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000852216 | SCV005075835 | pathogenic | Hermansky-Pudlak syndrome | 2024-04-02 | criteria provided, single submitter | clinical testing | Variant summary: HPS6 c.779G>A (p.Gly260Glu) results in a non-conservative amino acid change located in the BLOC-2 complex member HPS6, N-terminal domain (IPR046823) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 8e-06 in 250764 control chromosomes. c.779G>A has been reported in the literature as a biallelic homozygous genotype in individuals affected with Hermansky-Pudlak Syndrome (example, Hull_2016 cited in Han_2018, Downes_2019). These data indicate that the variant is very likely to be associated with disease. The following publications have been ascertained in the context of this evaluation (PMID: 31064749, 30369044, 31898847, 26823395, 35054407). ClinVar contains an entry for this variant (Variation ID: 627382). Based on the evidence outlined above, the variant was classified as pathogenic. |
Fulgent Genetics, |
RCV005029422 | SCV005663040 | pathogenic | Hermansky-Pudlak syndrome 6 | 2024-04-03 | criteria provided, single submitter | clinical testing |